Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Folia Med (Plovdiv) ; 65(4): 569-576, 2023 Aug 31.
Article in English | MEDLINE | ID: mdl-37655374

ABSTRACT

INTRODUCTION: Exercise-induced desaturation is common in patients with moderate to severe chronic obstructive pulmonary disease (COPD). It provides additional information about physical capacity and disease evolution, and it is an important predictor of mortality.


Subject(s)
Exercise , Pulmonary Disease, Chronic Obstructive , Humans , Walk Test , Patients , Pulmonary Disease, Chronic Obstructive/diagnosis , Physical Examination
2.
Folia Med (Plovdiv) ; 65(1): 177-182, 2023 Feb 28.
Article in English | MEDLINE | ID: mdl-36855992

ABSTRACT

The term 'athletic heart syndrome' (AHS) is used to describe specific circulatory and morphological changes in individuals who participate in sports competitions. The syndrome is characterized by normal cardiac function and reversible myocardial remodelling.The incidence and severity of the post-COVID-19 cardiac pathology in active athletes are so far unclear. One of the complications involving the heart is myocarditis. We present a case of a 23-year-old rower after having a moderate COVID-19 infection. Electrocardiograms showed evidence of a shift in conduction and rhythm disturbances ranging from Group 1 (normal ECG findings) to Group 2 (abnormal ECG findings) on the background of an AHS. Echocardiography (with new methods of evaluating deformity - Global Longitudinal Strain) revealed an area with mildly reduced left ventricular deformity around the apex. To assess the subtle alterations in the myocardium, magnetic resonance imaging was used and focal myocarditis was detected. In our patient, considering the degree of severity of his COVID-19 infection - a moderate one, a decision was taken to perform a clinical and instrumental reassessment of his cardiovascular complications 6 months after the infection.This clinical case presents two substantial issues. First, is the AHS more susceptible to rhythm and conduction disturbances after a COVID-19 infection than that of a person who does not actively participate in sports? Second, what the reversibility or the definitive nature of these disturbances is, and how this impacts the prognosis associated with an active sporting activity.


Subject(s)
COVID-19 , Cardiomegaly, Exercise-Induced , Myocarditis , Humans , Young Adult , Adult , Myocarditis/diagnostic imaging , Myocarditis/etiology , COVID-19/complications , Myocardium , Hypertrophy
3.
Folia Med (Plovdiv) ; 64(1): 156-161, 2022 Feb 28.
Article in English | MEDLINE | ID: mdl-35851895

ABSTRACT

A 27-year-old patient presented with a 3-month history of episodic headaches and persistently rising blood pressure (up to 240/120). The clinical, laboratory, and instrumental findings (episodes of severe hypertension, increased levels of metanephrine in urine, and MRI showing a mass of 5.1×5.5 cm in diameter) led us to the diagnosis of pheochromocytoma of the right adrenal grand. Preoperative medication included alpha blockers, calcium channel blockers, and plasma. The right adrenal gland was completely removed using the retroperitoneal access. During the extraction of the tumour, a ventricular tachycardia was recorded after which acute heart failure issued. In the first few hours, echocardiographic imaging showed a reduced EF of 9% - catecholamine-induced cardiomyopathy. The patient underwent a complex and adequate reanimation in the intensive care unit which lasted 20 days. A slow but steady increase in the ejection fraction along with a decrease in congestion was observed. Magnetic resonance imaging was used to confirm the normalisation of myocardial morphology. A German histological laboratory was used to confirm the benign form of the tumour. For the next three months, the patient was on a standard therapy with beta blockers, angiotensin-converting-enzyme inhibitor and mineralocorticoid antagonists. Тhe catecholamine surge during the removal of a large pheochromocytoma could lead to severe cardio-vascular complication, even with a complete and adequate preoperative protective medication. The reversibility of the process implies the necessity of an adequate and timely postoperative treatment for a complete involution of the pathomorphological changes.


Subject(s)
Adrenal Gland Neoplasms , Cardiomyopathies , Pheochromocytoma , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/diagnostic imaging , Adrenal Gland Neoplasms/surgery , Adult , Blood Pressure , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/etiology , Catecholamines , Humans , Pheochromocytoma/complications , Pheochromocytoma/diagnostic imaging , Pheochromocytoma/surgery
4.
Folia Med (Plovdiv) ; 64(5): 740-745, 2022 Oct 31.
Article in English | MEDLINE | ID: mdl-36876527

ABSTRACT

INTRODUCTION: Based on many previous studies, liver cirrhosis is traditionally associated with cardiac dysfunction. The main clinical features of cirrhotic cardiomyopathy include attenuated systolic contractility in response to physiologic or pharmacologic strain, diastolic dysfunction, electrical conductance abnormalities, and chronotropic incompetence. Previous studies have found that the levels of brain natriuretic peptide (BNP) and its precursor the N-terminal pro B-type natriuretic peptide (NT-proBNP) are elevated in cirrhosis with systolic as well as diastolic dysfunction.


Subject(s)
Cardiomyopathies , Natriuretic Peptide, Brain , Humans , Peptide Fragments , Liver Cirrhosis
6.
Folia Med (Plovdiv) ; 59(3): 336-343, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28976895

ABSTRACT

BACKGROUND: The risk of excessive bleeding often prompts physicians to interrupt the antiplatelet agents as acetylsalicilyc acid and clopidogrel before dental extractions which puts patients at risk of adverse thrombotic events. AIM: To assess the bleeding risk during dental extractions in patients with continued antiplatelet therapy. MATERIALS AND METHODS: The study included 130 patients (64 men and 66 women) aged between 18 and 99 years old. Sixty-eight of the patients received 100 mg acetilsalicilic acid (ASA); these were divided into two groups: 34 patients continued taking ASA and 34 patients stopped it 72 hours before extraction. Sixty-two of the patients were treated with 75 mg clopidogrel; these were also divided into two groups: 31 continued taking clopidogrel and 31 patients stopped it 72 hours before extractions. Extraction was performed under local anaesthesia as no more than 3 teeth per visit were extracted. Local haemostasis with gelatine sponge and/or suturing was used to control bleeding. RESULTS: Mild bleeding was observed most frequently in the first 30 minutes, successfully managed by local haemostasis. Only 1 patient in the control and 1 in the experimental group receiving ASA reported mild bleeding in the first 24 hours, controlled by compression with gauze. No major haemorrhage requiring emergency or more than local haemostasis occurred. No statistically significant difference in bleeding between two groups was found. CONCLUSION: Single and multiple dental extractions in patients receiving acetylsalicylic acid or clopidogrel can be safely performed without discontinuation of the therapy with provided appropriate local haemostasis.


Subject(s)
Aspirin/administration & dosage , Clopidogrel/administration & dosage , Hemorrhage/chemically induced , Platelet Aggregation Inhibitors/administration & dosage , Tooth Extraction/adverse effects , Administration, Oral , Adult , Aged , Aged, 80 and over , Aspirin/adverse effects , Bulgaria , Clopidogrel/adverse effects , Cohort Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Hemorrhage/physiopathology , Humans , Male , Middle Aged , Patient Safety , Platelet Aggregation Inhibitors/adverse effects , Prospective Studies , Risk Assessment , Tooth Extraction/methods , Treatment Outcome , Withholding Treatment , Young Adult
7.
Clin Lab ; 56(7-8): 291-302, 2010.
Article in English | MEDLINE | ID: mdl-20857893

ABSTRACT

BACKGROUND: The idea that statin therapy decreases asymmetric dimethylarginine through lowering low-density lipoprotein cholesterol levels seems logic. However, controversy exists in the literature concerning this issue. This study compares the effect of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine levels in patients with newly detected severe hypercholesterolemia (after targeted LDL levels of < or = 2.6 mmol/L are reached). METHODS: The study included 120 adult patients with newly detected severe hypercholesterolemia (total cholesterol > or = 7.5 mmol/L and low-density lipoprotein cholesterol > or = 4.9 mmol/L). Asymmetric dimethylarginine levels were determined by enzyme-linked immunosorbent assay, total homocystein by the high performance liquid chromatography method. RESULTS: A statistically significant decrease exists in total cholesterol, triglycerides, low-density lipoprotein cholesterol and apolipoprotein-B levels as well as apolipoprotein-B/apolipoprotein-A1 index following one month of 40 mg simvastatin therapy (P < 0.001). Asymmetric dimethylarginine and total homocystein levels were also decreased but the difference was not significant (p = 0.571; p = 0.569). A dose-dependent effect was established comparing the influence of moderate (40 mg) to high (80 mg) simvastatin doses on the tested atherogenic biomarkers (lipid profile, apolipoprotein-A1, apolipoprotein-B). Asymmetric dimethylarginine and total homocystein levels showed a statistically significant decrease with 80 mg simvastatin (p < 0.001; p = 0.038). In the group of 40 patients, who had reached LDL-cholesterol target levels on 80 mg simvastatin, a reduction in ADMA levels demonstrated a statistically significant correlation with the reduction of LDL-cholesterol (r(xy) = 0.355; p < 0.01) and of Apo-B (r(xy) = 0.508; p < 0.001). The backward selection process selected percent ApoB-change as the most important statistically significant factor related to percent ADMA-change (F = 21.127; p = 0.001; R2 = 0.265). CONCLUSIONS: Optimizing the target values of low-density lipoprotein cholesterol to the moderate dose (40 mg) of simvastatin has no effect on asymmetric dimethylarginine and total homocysteine in contrast to high dose (80 mg) after targeted LDL of < or = 2.6 mmol/L levels are reached in patients with newly detected severe hypercholesterolemia.


Subject(s)
Anticholesteremic Agents/therapeutic use , Arginine/analogs & derivatives , Homocysteine/blood , Hypercholesterolemia/drug therapy , Simvastatin/therapeutic use , Adult , Arginine/blood , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Female , Humans , Hypercholesterolemia/blood , Lipids/blood , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...